FY2025 EPS Estimates for TScan Therapeutics Cut by Wedbush

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of TScan Therapeutics in a report released on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.98) per share for the year, down from their previous forecast of ($0.97). Wedbush currently has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.96) EPS and FY2028 earnings at ($0.89) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

A number of other research firms have also recently issued reports on TCRX. Barclays cut their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday. Finally, Needham & Company LLC decreased their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics has a consensus rating of “Buy” and an average price target of $9.20.

TScan Therapeutics Stock Down 4.8 %

Shares of NASDAQ TCRX opened at $1.98 on Monday. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. The company’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $3.99.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $61,000. Woodline Partners LP lifted its stake in TScan Therapeutics by 6.7% during the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after acquiring an additional 7,282 shares in the last quarter. Squarepoint Ops LLC purchased a new position in TScan Therapeutics during the 4th quarter worth $59,000. Tang Capital Management LLC bought a new stake in shares of TScan Therapeutics in the 4th quarter worth $358,000. Finally, Shay Capital LLC purchased a new stake in shares of TScan Therapeutics in the fourth quarter valued at about $65,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.